title: Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation.
abstract: Interferon (IFN) therapy is the only treatment strategy for hepatitis C virus (HCV) infection after liver transplantation (LT), but prophylactic and treatable IFN therapy after LT has been shown to be insufficient due to the adverse effects of IFN and rivabirin. In this paper, we describe the disappearance of HCV after LT without IFN therapy in the presence of residual viremia on the day of LT. We herein report our findings since this is considered an important case for the anti-HCV strategy of post LT. A 60-year old woman with LC and HCC was referred to Nagasaki University Hospital in August 2004. After she underwent LT on February 18, 2005, we injected peg-IFN-alpha-2a the 11th time at 18 wk and HCV-RNA was still positive in the serum at LT. The serum HCV-RNA was negative one month after operation and subsequently dissolved 15 mo after operation without IFN therapy. As a result, we speculate that if HCV-RNA is positive while HCV core antigen is negative before LT, then it may lead to clearance of HCV after LT. Therefore long acting peg-IFN-alpha-2a is thus considered a potentially effective agent for the treatment of HCV-related cirrhosis before LT.
authors: The First Department of Internal Medicine, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. ichikawa@net.nagasaki-u.ac.jp
authors: Tatsuki
authors: T
authors: Ichikawa
authors: Kazuhiko
authors: K
authors: Nakao
authors: Keisuke
authors: K
authors: Hamasaki
authors: Takuya
authors: T
authors: Honda
authors: Hidetaka
authors: H
authors: Shibata
authors: Mana
authors: M
authors: Akahoshi
authors: Susumu
authors: S
authors: Eguchi
authors: Mitsuhisa
authors: M
authors: Takatsuki
authors: Takashi
authors: T
authors: Kanematsu
authors: Katsumi
authors: K
authors: Eguchi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D005260:Female; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000601:surgery; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation; D019520:Living Donors; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D014766:Viremia / Q000188:drug therapy*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
references: Am J Transplant. 2005 Jan;5(1):118-24
references: 15636619
references: Liver Transpl. 2003 Sep;9(9):905-15
references: 12942451
references: Gastroenterology. 2006 Nov;131(5):1452-62
references: 17101321
references: Am J Transplant. 2005 Aug;5(8):1909-13
references: 15996238
references: J Hepatol. 2000 Apr;32(4):673-84
references: 10782918
references: J Hepatol. 2003 Sep;39(3):389-96
references: 12927925
references: Antivir Ther. 2004 Aug;9(4):491-7
references: 15456079
references: Liver Transpl. 2006 Feb;12(2):207-16
references: 16447184
references: Liver Transpl. 2003 Nov;9(11):S95-S100
references: 14586903
references: Hepatology. 2005 Feb;41(2):289-98
references: 15660392
references: Gut. 2003 Feb;52(2):283-7
references: 12524414
references: Liver Transpl. 2002 Apr;8(4):350-5
references: 11965579
references: Hepatology. 2002 Mar;35(3):680-7
references: 11870384
references: Liver Transpl. 2006 Jun;12(6):912-9
references: 16489583
references: Liver Transpl. 2004 Feb;10(2):199-207
references: 14762857
references: Hepatology. 2005 Aug;42(2):255-62
references: 16025497